Codexis Funding Round

11/10/2026

Debt

$60,000,000

Undisclosed

Codexis will use the proceeds from its $60 million senior secured term loan facility with Trinity Capital primarily to refinance its existing debt held by Innovatus Life Sciences Lending Fund I, which was repaid in full for approximately $43.6 million, including accrued interest, fees and expenses. The refinancing provides Codexis with greater financial flexibility to advance its growth initiatives in the small interfering RNA (siRNA) therapeutics sector. The company also plans to industrialize its proprietary ECO Synthesis Manufacturing Platform, achieve important Good Manufacturing Practice (GMP) manufacturing milestones and scale up oligonucleotide synthesis capabilities to strengthen its position in the RNA therapeutics manufacturing industry.

Publicly-held

Biopharmaceutical

200 Penobscot Dr.
Redwood City, CA 94063
USA

WE ARE BIOCATALYSIS Codexis is a leading developer of biocatalysts. A biocatalyst is an enzyme or microbe that initiates and accelerates a chemical reaction.